… 29.42%; p=0.043) diagnoses were lower for TIO+OLO with 24% reduced risk of experiencing
pneumonia/acute bronchitis/bronchiolitis diagnosis (adjusted HR=0.76; 95% CI: 0.60-0.97; …

… note that long-acting muscarinic agents/beta2-agonists (LAMA+LABA) are the preferred
first-line … with a diagnosis of COPD (or pneumonia/acute bronchitis/bronchiolitis) in any position. …

… For the sample size calculation, we considered a mean duration of severe symptoms in
uncomplicated acute bronchitis of 5.5 days (SD 4.5) and a reduction of 1.5 days as a clinically …

… Inhaled long‐acting beta2‐agonists (LABA) and long‐acting muscarinic antagonists (LAMA)
are … Beta2‐agonists stimulate adenylyl cyclase activity and directly cause smooth muscle …

… The excessive prescribing of short-acting beta2-agonists (SABAs), an indicator of poorly
controlled asthma and a risk factor for asthma attacks, remains problematic despite proliferating …

… the acute unwanted effects of various beta2 agonist medications are discussed. When beta2
agonists … In this review, acute unwanted effects of beta2 agonists will be considered under …

… antagonists (LAMAs) plus long-acting beta2-agonists (LABAs) for patients in Groups BD who
… a diagnosis code for pneumonia and/or acute bronchitis/bronchiolitis in any position (codes …

… according to the response to short acting beta2 agonists or the effect of a therapeutic trial …
In JPGL2017, the transdermal patch and oral beta2 agonists are positioned as drugs within …

… examined the use of b2-agonists for cough in acute bronchitis in patients without underlying
lung … Beta2-agonists for acute cough or a clinical diagnosis of acute bronchitis (review). …

… In patients with serum eosinophilia> 300 cells/microL, inhaled corticosteroids (ICS) with
long-acting beta2 agonists (LABA) is recommended. This is an approach toward phenotyping …